Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56 Percent

Algernon Pharmaceuticals Inc., formerly known as Breathtec, a UF startup, announced that NP-120, its repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF), showed superiority in reducing fibrosis over two globally approved therapies for IPF, Pirfenidone and Nintedanib, in a well-established in vivo animal model study of IPF.